Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 53, Issue 2, Pages 621-630Publisher
IOS PRESS
DOI: 10.3233/JAD-160022
Keywords
Alzheimer's disease; amyloid; cognition; platelet; serotonin
Categories
Funding
- Konung Gustaf V och Drottning Victorias Stiftelse
- Hultmans Stiftelse
Ask authors/readers for more resources
Introduction: Serotonin (5-HT) is involved in the pathology of Alzheimer's disease (AD). Objective: We aimed to measure 5-HT level in platelets in AD and explore its association with cerebrospinal fluid (CSF), AD biomarkers (amyloid-beta 1-42 (A beta(42)), total tau (t-tau), and phosphorylated tau (p-tau)), and clinical symptoms. Methods: 15 patients with AD and 20 patients with subjective cognitive impairment (SCI) were included. 5-HT metabolites were measured, in a specific fraction, using high performance liquid chromatography with electrochemical detection (HPLC-ECD). Results: Significantly lower 5-HT concentrations were observed in AD patients compared to SCI patients both after normalization against total protein (p = 0.008) or platelet count (p = 0.019). SCI patients with lower 5-HT level have higher AD CSF biomarkers, total tau (p = 0.026) and tau/A beta(42) ratio (p = 0.001), compared to those with high 5-HT levels. Conclusion: AD patients have reduced platelet 5-HT levels. In SCI, lower 5-HT content was associated with a higher AD-CSF biomarker burden.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available